Impact of Complementary Mistletoe Extract Treatment on Quality of Life in Breast, Ovarian and Non-small Cell Lung Cancer Patients. A Prospective Randomized Controlled Clinical Trial

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 303-309

  Piao, B K ^a   Wang, Y X ^b   Xie, G R ^c   Mansmann, U ^d   Matthes, H ^e   Beuth, J ^f   Lin, H S ^a  

^a Guanganmen Hospital   (China)

^b LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^c Department of Breast Cancer   (China)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Gemeinschaftskrankenhaus Havelhohe   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cancer patients; Mistletoe extract; Quality of life; Randomized controlled trial

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; LENTINAN; MITOMYCIN; NAVELBINE; TEGAFUR; VINDESINE; VISCUM ALBUM EXTRACT;

ALTERNATIVE MEDICINE; ANGIONEUROTIC EDEMA; ARTICLE; BIOMETRY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHINESE MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFLAMMATION; INJECTION SITE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISCUM ALBUM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MISTLETOE; OVARIAN NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS; PLANT PROTEINS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TOXINS, BIOLOGICAL;

EID: 1442350530     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Büssing A: Mistletoe. The Genus Viscum. Harwood Academic Publishers, Singapore, 2000.
2. Kienle G S, Berrino F, Büssing A, Portalupi E, Rosenzweig S and Kiene H: Mistletoe in cancer-a systematic review in controlled clinical trials. Europ J Me Res 8: 109-119, 2003.
3. Beuth J: Grundlagen der Komplementäronkologie. Theorie und Praxis, Hippokrates Verlag, Stuttgart, 2002.
4. Wagner H: Viscum album-die Mistel. Deutsche Apotheker Zeitung 124: 1429-1432, 1984.
5. Büssing A: Biologische Wirkungen der Mistel. Zeitschrift für Onkologie 31: 35-43, 1999.
6. Beuth J: Clinical relevance of immunoactive mistletoe lectin-1. Anti Cancer Drugs 8: 53-55, 1997.
7. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J and Beuth J: Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektinnormiertem Mistelextrakt-eine epidemiologische, kontrollierte, multizentrische retrolektive Kohortenstudie. Deutsche Zeitschrift für Onkologie 34: 106-114, 2002.
8. Lenartz D, Dott U, Menzel J, Schierholz JM and Beuth J: Survival of patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20: 2073-2076, 2000.
9. Kubasova T, Pfueller U, Koeteles GJ, Csollak M and Eifler R: Comparative studies in some cellular and immunological effects of mistletoe isolectins in vitro. In: van Driessche E (Ed) Lectins: Biology, Biochemistry, Clinical Biochemistry Vol 11, Textop Hellerup 240-244, 1996.
10. Büssing A, Rosenberger C, Stumpf C and Schietzel M: Entwicklung lymphozytärer Subpopulationen bei Tumorpatienten nach subkutaner Applikation von Mistelextrakten, Forschende Komplementärmedizin 6: 196-204, 1999.
11. Heiny BM and Beuth J: Mistletoe extracts standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342, 1994.
12. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K and Kumada K: A multiinstitutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepato-Gastroenterology 46: 2662-2668, 1999.